98%
921
2 minutes
20
Background: We performed this study to investigate the effect of intraoperative brainstem auditory evoked potential (IBAEP) changes on the development of postoperative nausea and vomiting (PONV) after microvascular decompression (MVD) for neurovascular cross compression.
Methods: A total of 373 consecutive cases were treated with MVD. The use of rescue antiemetics after surgery was used as an objective indicator of PONV. IBAEP monitoring was routinely performed in all.
Results: The use of rescue antiemetics was significantly associated with female sex (OR = 3.427; 95% CI, 2.077-5.654; P < 0.001), PCA use (OR = 3.333; 95% CI, 1.861-5.104; P < 0.001), and operation time (OR = 1.017; 95% CI, 1.008-1.026; P < 0.001). A Wave V peak delay of more than 1.0 milliseconds showed a significant relation with the use of rescue antiemetics (OR = 1.787; 95% CI, 1.114-2.867; P = 0.016) and a strong significant relation with the use of rescue antiemetics more than 5 times (OR = 2.426; 95% CI, 1.372-4.290; P = 0.002).
Conclusions: A wave V peak delay of more than 1.0 milliseconds might have value as a predictor of PONV after MVD. More detailed neurophysiological studies will identify the exact pathophysiology underlying PONV after MVD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.wneu.2024.03.041 | DOI Listing |
Drug Des Devel Ther
September 2025
Department of Anesthesiology, Peking University People's Hospital, Beijing, People's Republic of China.
Background: The dopamine D2/D3 antagonist amisulpride has demonstrated its superiority and efficacy in prophylaxis of postoperative nausea and vomiting (PONV). Given the branded intravenous amisulpride (Barhemsys) has not been approved in China, there is unmet clinical need for amisulpride. Our primary objective was to ascertain the efficacy and safety of the generic intravenous amisulpride (QLG2069) in the prophylaxis of PONV.
View Article and Find Full Text PDFIntroduction: Breast cancer incidence has been rising in recent years, particularly among younger women, and it is now the leading cancer among Indian females. Acute postoperative pain is a significant concern, often deterring patients from surgery. Combining regional anesthesia with intravenous analgesics can improve postoperative outcomes.
View Article and Find Full Text PDFAnticancer Res
September 2025
Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan
Background/aim: This study aimed to investigate the efficacy of olanzapine, an antiemetic agent used to prevent chemotherapy-induced nausea and vomiting (CINV), at 5 and 10 mg/day, by chemotherapy emetogenic risk, and to evaluate the efficacy of low dose olanzapine at 2.5 mg/day.
Materials And Methods: PubMed and Web of Science were searched to identify studies evaluating the efficacy of olanzapine in CINV prevention from database inception up to August 31, 2023.
BMC Med
August 2025
Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
Background: This phase I trial aimed to assess the pharmacokinetics (PK), safety, and preliminary efficacy of a single dose of HR20013 (mixed formulation of fosrolapitant and palonosetron) plus dexamethasone in patients with malignant solid tumors.
Methods: Solid tumor patients who were naive to cisplatin-based chemotherapy and scheduled to receive the single-day cisplatin-based chemotherapy were enrolled. Patients would receive a single intravenous infusion of HR20013 (Day 1) before cisplatin-based chemotherapy, alongside oral dexamethasone (Day 1, 12 mg, once a day; Day 2-4, 3.
Surg Endosc
August 2025
Metabolic and Obesity Surgery Unit, ARNAS G. Brotzu, Cagliari, Italy.
Introduction: Obesity is a major global health issue requiring tailored anesthetic and analgesic strategies due to associated physiological and pharmacokinetic changes. The Enhanced Recovery After Bariatric Surgery (ERABS) protocol has been introduced to optimize perioperative care, but its implementation remains inconsistent. This pilot study investigates the integration of a perioperative clinical hypnosis (CH) protocol with ERABS to assess its effects on postoperative pain, nausea, and analgesic/antiemetic drug consumption in patients undergoing bariatric and metabolic surgery (BMS).
View Article and Find Full Text PDF